If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wonder what symptoms to watch for. Decades of pharmacovigilance and post-marketing studies have established a clear causal link between Tysabri and PML, a rare but serious brain infection. This page explains the condition, its early signs, and how it is monitored.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri regarding this risk, emphasizing that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical trial data document the occurrence of PML in patients receiving Tysabri. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1,043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data illustrate that PML can develop after varying durations of exposure, including relatively short courses of treatment. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain, thereby reducing inflammatory activity in multiple sclerosis. However, this immunosuppressive effect in the central nervous system can impair immune surveillance against JCV, allowing the virus to reactivate and cause PML. The risk is further elevated in patients with prior immunosuppressant use, which may compound the immune compromise.
Regarding the adequacy of warnings, the FDA-approved labeling includes a boxed warning that clearly states Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also specifies that healthcare professionals should monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure that prescribers, patients, and pharmacies are educated about the risk. These measures constitute a comprehensive risk communication framework. For affected patients, causation considerations involve establishing that PML developed during or after Tysabri therapy, in the absence of other significant immunosuppressive conditions. The known risk factors—anti-JCV antibody status, treatment duration, and prior immunosuppressant use—provide a basis for assessing individual risk. The timeline between exposure and documented harm can vary, as evidenced by cases occurring after eight doses or after longer treatment periods. Clinical presentation of PML includes progressive neurological deficits, and diagnosis is confirmed by brain imaging and detection of JCV DNA in cerebrospinal fluid. In summary, the evidence establishes a clear causal link between Tysabri and PML, supported by pharmacological mechanism, clinical trial data, and FDA risk communication. The warnings are robust, but the risk remains significant, particularly in patients with identified risk factors. Healthcare providers must carefully weigh benefits and risks when prescribing Tysabri and maintain vigilant monitoring for PML symptoms.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that typically leads to death or severe disability. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the brain, reducing inflammation but also impairing immune surveillance against JC virus. This allows the virus to reactivate and cause PML. The risk is compounded by prior immunosuppressant use.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.